233 – Cancer Panel + VitD + HA + Chem12

*This panel may be listed as [233b] – indicating that the Neoplasia Index is modified for specific use in Lymphoma to improve sensitivity and specificity for that application.  All other features remain the same.

Background:

The VDI Cancer Panel is for the diagnosis and monitoring of cancer in the sick dog or cat.  Unifying a blood marker of abnormal cell proliferation, Thymidine Kinase Type 1 (TK1) and inflammatory marker CRP or HPT (species dependent) into the Neoplasia Index­, the Cancer Panel is a Rule-in for neoplasia.   VDI provides context-sensitive results interpretation and clinical review on all Cancer Panels.  Learn More.

Type-specific cancer panels may be available to improve diagnostic performance in those cases. (GI Lymphoma, Cancer Panel Lymphoma, Pre-Stem Cell Panel).

Vitamin D is the most important hormone in the body and sufficient levels are anti-proliferative, pro-differentiating, and anti-inflammatory: all involved in cancer pathogenesis.  VDI provides patient-specific dosing guidelines to get patients to sufficiency.

Hyaluronic Acid (HA) is a marker of degenerative joint disease (DJD).  In dogs or cats with moderate to advanced DJD, mechanical damage to the joints especially after higher-than-usual activity, may increase TK1 levels slightly due to cellular death at the site of damage.

Basic Chem12 includes: TP, Alb, Glob, A/G ratio, BUN, Creatinine, BUN/Creatinine, ALT, ALP, Total Bili, Glucose, Calcium.

Clinical Applications:

1. Suspected Cancer
   • Identified mass
   • ADR (Ain’t Doing Right)
   • Suspicious signs/imaging
2. Confirmed Cancer
   • Monitor Therapy Efficacy
   • Monitor disease progression
   • Determine remission & identify early signs of relapse
   • Identify metastatic disease

Recommendations:

The Cancer Panel should be performed prior to administration of steroids, chemo, NSAIDs or other therapy whenever possible.  VDI can interpret results around the presence of therapy, but please be sure to indicate on the Test Requisition Form any medications at the time of draw.

Repeat testing (monitoring) is suggested at varying time windows depending on the patient status, diagnosis, and application.  Contact VDI for consultation on any case to determine the best repeat test window.